Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company’s programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. For more information visit www.enterothera.com.
Entero Therapeutics is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
Entero’s niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients. Two additional formulations of niclosamide, FW-UC (ulcerative colitis) and FW-CD (Crohn’s disease) are expected to enter the clinic in 2022 and 2023, respectively.
Entero is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
The Company is headquartered in Boca Raton, Florida with clinical operations in Hayward, California. For more information visit www.firstwavebio.com.
Company Details
- Employees
- 9
- Founded
- -
- Address
- 777 Yamato Road,
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.enterothera.com
- Keywords
- Gastrointestinal diseases, Gastrointestinal, GI diseases, GI health, Celiac, Celiac disease, Gluten Intolerance, Gluten-free diet, Gluten-free, Gluten, Latiglutenase, Gastroparesis, Capeserod, Lipase, Pancreatitis, Cystic Fibrosis, Adrulipase, Therapeutics.
- HQ
- Boca Raton, FL
Entero Therapeutics (Nasdaq: Ento) Questions
Entero Therapeutics (Nasdaq: Ento)'s website is https://www.enterothera.com
Entero Therapeutics (Nasdaq: Ento)'s LinkedIn profile is https://www.linkedin.com/company/enterothera
Entero Therapeutics (Nasdaq: Ento) has
9 employees.
View email and phone details for 9
employees at Entero Therapeutics (Nasdaq: Ento).
Entero Therapeutics (Nasdaq: Ento)'s industry is
Pharmaceutical Manufacturing
Entero Therapeutics (Nasdaq: Ento)'s top competitors are
Synlogic,
Gritstone Bio,
Inhibikase Therapeutics, Inc.,
Plus Therapeutics, Inc.,
Catamaran Bio,
Athersys,
Virometix Ag,
Mei Pharma,
Vbi Vaccines Inc.,
An2 Therapeutics.
Entero Therapeutics (Nasdaq: Ento)'s categories are Pharmaceutical Manufacturing
Entero Therapeutics (Nasdaq: Ento)'s founding year is 2014
